Government-Owned Inventions; Availability for Licensing, 47755 [2017-22147]

Download as PDF Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices Contact Person: Angela Y Ng, Ph.D., MBA, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6200, MSC 7804, Bethesda, MD 20892, 301–435– 1715, nga@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Pregnancy, Placentation, and Neonatology. Date: November 9, 2017. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Gary Hunnicutt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6164, MSC 7892, Bethesda, MD 20892, 301–435– 0229, gary.hunnicutt@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: October 6, 2017. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2017–22139 Filed 10–12–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve commercialization of results of federally-funded research and development. Foreign patent asabaliauskas on DSKBBXCHB2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:05 Oct 12, 2017 Jkt 244001 applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology follows. Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes Description of Technology: The invention pertains to the use of glucan encapsulated non-immunostimulatory small interfering RNAs (siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid signaling molecules that act on the same cannabinoid receptors that recognize and mediate the effects of endo- and phytocannabanoids. EC receptor CB1R activation is implicated in the development of obesity and its metabolic consequences, including insulin resistance and type 2 diabetes. Beta-cell loss has been demonstrated in a Zucker diabetic fatty (ZDF) rat model of type-2 diabetes through CB1Rmediated activation of a macrophagemediated inflammatory response. Conversely, rats treated with a peripheral CB1R antagonist restores normoglycemia and preserves beta-cell function. Similar results are seen following selective in vivo knockdown of macrophage CB1R by daily treatment of ZDF rats with the instant D-glucanencapsulated CB1R Small interfering RNA (siRNA). Knock-down of CB1R with using glucan encapsulated siRNA may represent a new commecializable method of treating type-2 diabetes or preventing the progression of insulin resistance to overt diabetes. Potential Commercial Applications: Treatment of obesity, insulin resistance, and diabetes. Development Stage: In vivo data available. Inventors: George Kunos, Tony Jourdan (NIAAA), Michael Czech, Myriam Aouadi. Intellectual Property: HHS Reference No. E–103–2013/0, U.S. Provisional Patent Application 61/839,239 filed June 25, 2013, International Patent Application PCT/US2014/043924 filed June 24, 2014, European Patent Application 14818342.9 filed June 24, 2014 and U.S. Patent Application 14/ 900,951 filed June 24, 2014. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@nih.gov. Dated: October 5, 2017. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2017–22147 Filed 10–12–17; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 47755 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Neurological Sciences Training Initial Review Group; NST–2 Subcommittee. Date: October 23, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Crystal City, 2399 Jefferson Davis Highway, Arlington, VA 22202. Contact Person: Elizabeth Webber, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892–9529, (301) 496–1917, Webbere@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; R13 Review. Date: October 26, 2017. Time: 9:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Ernie Lyons, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892–9529, (301) 496–4056, lyonse@ninds.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; F32 and K22 Review. Date: November 2–3, 2017. Time: 8:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\13OCN1.SGM 13OCN1

Agencies

[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Page 47755]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22147]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing. A description of the 
technology follows.

Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for 
Treating Type 2 Diabetes

    Description of Technology: The invention pertains to the use of 
glucan encapsulated non-immunostimulatory small interfering RNAs 
(siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid 
signaling molecules that act on the same cannabinoid receptors that 
recognize and mediate the effects of endo- and phytocannabanoids. EC 
receptor CB1R activation is implicated in the development of obesity 
and its metabolic consequences, including insulin resistance and type 2 
diabetes. Beta-cell loss has been demonstrated in a Zucker diabetic 
fatty (ZDF) rat model of type-2 diabetes through CB1R-mediated 
activation of a macrophage-mediated inflammatory response. Conversely, 
rats treated with a peripheral CB1R antagonist restores normoglycemia 
and preserves beta-cell function. Similar results are seen following 
selective in vivo knockdown of macrophage CB1R by daily treatment of 
ZDF rats with the instant D-glucan-encapsulated CB1R Small interfering 
RNA (siRNA). Knock-down of CB1R with using glucan encapsulated siRNA 
may represent a new commecializable method of treating type-2 diabetes 
or preventing the progression of insulin resistance to overt diabetes.
    Potential Commercial Applications: Treatment of obesity, insulin 
resistance, and diabetes.
    Development Stage: In vivo data available.
    Inventors: George Kunos, Tony Jourdan (NIAAA), Michael Czech, 
Myriam Aouadi.
    Intellectual Property: HHS Reference No. E-103-2013/0, U.S. 
Provisional Patent Application 61/839,239 filed June 25, 2013, 
International Patent Application PCT/US2014/043924 filed June 24, 2014, 
European Patent Application 14818342.9 filed June 24, 2014 and U.S. 
Patent Application 14/900,951 filed June 24, 2014.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
shmilovm@nih.gov.

    Dated: October 5, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-22147 Filed 10-12-17; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.